| 摘要 |
<p>Attenuated vaccine against influenza contains as active ingredient a strain of attenuated H3N2 type influenza virus resistant to serum inhibitors. The strain is influenza virus strain P/76/7. Used as vaccine against influenza suitable for intranasal administration. Pref. a unit dose of the vaccine contains at least 107 DIO50 (infective dose of 50% of inoculated eggs) of the P/76/7 virus strain. The parent patent BE 819865 describes a method of obtaining stable strains of influenza virus type A (H3N2) which are resistant to serum inhibitors. Each year the serotype of influenza virus type A in the world differs slightly from the strains observed the previous year; this antigenic modification causing problems for immunisation against influenza type A. To obtain maximum effect the vaccinal antigen must be nearest to the dominant virus and thus influenza vaccines are periodically adapted to give maximum protection against these new strains, the present addition comprising such a modification.</p> |
